Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 3
1985 1
1987 3
1988 3
1989 4
1990 5
1992 6
1993 1
1994 6
1995 5
1996 1
1997 5
1998 9
1999 3
2000 1
2001 1
2002 3
2003 3
2004 1
2005 6
2006 5
2007 2
2008 1
2009 1
2010 2
2011 2
2012 2
2013 5
2015 1
2016 4
2017 1
2018 4
2019 4
2020 7
2021 12
2022 8
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A, Agustoni F, Percivalle E, Borgetto S, Paulet A, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, Zavaglio F, Arena F, Lilleri D, Secondino S, Falzoni M, Schiavo R, Klersy C, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: sarasini a. ESMO Open. 2021 Oct;6(5):100272. doi: 10.1016/j.esmoop.2021.100272. Epub 2021 Sep 1. ESMO Open. 2021. PMID: 34543863 Free PMC article.
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A, Lilleri D, Agustoni F, Percivalle E, Borgetto S, Alessio N, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, Zavaglio F, Arena F, Secondino S, Falzoni M, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: sarasini a. ESMO Open. 2022 Feb;7(1):100359. doi: 10.1016/j.esmoop.2021.100359. Epub 2021 Dec 11. ESMO Open. 2022. PMID: 34973510 Free PMC article.
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Serra F, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: sarasini a. ESMO Open. 2022 Oct;7(5):100574. doi: 10.1016/j.esmoop.2022.100574. Epub 2022 Aug 5. ESMO Open. 2022. PMID: 36029652 Free PMC article.
Preliminary results on an autochthonous dengue outbreak in Lombardy Region, Italy, August 2023.
Cassaniti I, Ferrari G, Senatore S, Rossetti E, Defilippo F, Maffeo M, Vezzosi L, Campanini G, Sarasini A, Paolucci S, Piralla A, Lelli D, Moreno A, Bonini M, Tirani M, Cerutti L, Paglia S, Regazzetti A, Farioli M, Lavazza A, Faccini M, Rovida F, Cereda D, Baldanti F; Lombardy Dengue network; Lombardy Dengue Network. Cassaniti I, et al. Among authors: sarasini a. Euro Surveill. 2023 Sep;28(37):2300471. doi: 10.2807/1560-7917.ES.2023.28.37.2300471. Euro Surveill. 2023. PMID: 37707980 Free PMC article.
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS.
Baldanti F, Underwood MR, Stanat SC, Biron KK, Chou S, Sarasini A, Silini E, Gerna G. Baldanti F, et al. Among authors: sarasini a. J Virol. 1996 Mar;70(3):1390-5. doi: 10.1128/JVI.70.3.1390-1395.1996. J Virol. 1996. PMID: 8627655 Free PMC article.
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Alessio N, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: sarasini a. ESMO Open. 2022 Apr;7(2):100458. doi: 10.1016/j.esmoop.2022.100458. Epub 2022 Mar 11. ESMO Open. 2022. PMID: 35427842 Free PMC article.
Emerging viral infections in neonatal intensive care unit.
Tzialla C, Civardi E, Borghesi A, Sarasini A, Baldanti F, Stronati M. Tzialla C, et al. Among authors: sarasini a. J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 1:156-8. doi: 10.3109/14767058.2011.607588. Epub 2011 Aug 31. J Matern Fetal Neonatal Med. 2011. PMID: 21877999 Review.
Assessing Immunity to Rubella Virus: a Plea for Standardization of IgG (Immuno)assays.
Bouthry E, Furione M, Huzly D, Ogee-Nwankwo A, Hao L, Adebayo A, Icenogle J, Sarasini A, Revello MG, Grangeot-Keros L, Vauloup-Fellous C. Bouthry E, et al. Among authors: sarasini a. J Clin Microbiol. 2016 Jul;54(7):1720-1725. doi: 10.1128/JCM.00383-16. Epub 2016 May 4. J Clin Microbiol. 2016. PMID: 27147722 Free PMC article.
123 results